NURIX THERAPEUTICS, INC. Income Taxes Receivable, Current
NURIX THERAPEUTICS, INC. (NRIX) had Income Taxes Receivable, Current of $3.10 million as of 2021-05-31, per its 10-Q filed 2021-07-13.
Discontinued › Notes
us-gaap:IncomeTaxesReceivable · last filed 2021-07-13
- 2021-05-31: Income Taxes Receivable, Current $3.10M.
- 2021-02-28: Income Taxes Receivable, Current $4.00M.
- 2020-11-30: Income Taxes Receivable, Current $3.90M.
- 2020-08-31: Income Taxes Receivable, Current $3.90M.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2021-05-31 | $3.10M 10-Q · filed 2021-07-13 |
| 2021-02-28 | $4.00M 10-Q · filed 2021-04-13 |
| 2020-11-30 | $3.90M 10-K · filed 2021-02-16 |
| 2020-08-31 | $3.90M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |